C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/28 (2006.01) A61K 39/395 (2006.01)
Patent
CA 2706899
The present invention relates in a first aspect to a B-cell depleting anti- CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease.
La présente invention concerne en premier lieu un anticorps anti-CD20 de déplétion de cellule B ou un fragment d'anticorps se liant au CD20 pour le traitement du syndrome de fatigue chronique et de l'encéphalomyélite myalgique. En particulier, la présente invention concerne l'utilisation d'anticorps monoclonaux anti-CD20, ou de leurs fragments, adaptés de préférence à l'homme, pour le traitement du syndrome de fatigue chronique et/ou de l'encéphalomyélite myalgique sur un sujet atteint par une telle maladie.
Fluge Øystein
Mella Olav
Bergen Teknologioverforing As
Kirby Eades Gale Baker
LandOfFree
B-cell depleting agents, like anti-cd20 antibodies or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with B-cell depleting agents, like anti-cd20 antibodies or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B-cell depleting agents, like anti-cd20 antibodies or... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1967508